TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Get Free Report) CEO Mary Szela acquired 30,864 shares of the stock in a transaction on Tuesday, November 17th. The shares were acquired at an average cost of $2.31 per share, for a total transaction of $71,295.84. Following the completion of the transaction, the chief executive officer directly owned 1,105,854 shares in the company, valued at $2,554,522.74. The trade was a 2.87% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
TriSalus Life Sciences Stock Performance
TLSI stock traded down $0.28 during trading on Thursday, hitting $2.17. The company had a trading volume of 364,646 shares, compared to its average volume of 302,213. The firm has a 50-day moving average price of $3.90 and a 200-day moving average price of $4.26. The company has a quick ratio of 3.86, a current ratio of 4.22 and a debt-to-equity ratio of 47.60. The firm has a market cap of $133.62 million, a PE ratio of -4.43 and a beta of 0.50. TriSalus Life Sciences, Inc. has a 1-year low of $2.16 and a 1-year high of $7.95.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $12.88 million during the quarter, compared to analyst estimates of $14.02 million. On average, analysts expect that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current year.
Analyst Ratings Changes
Several analysts have recently weighed in on TLSI shares. Citigroup reaffirmed a “buy” rating on shares of TriSalus Life Sciences in a report on Tuesday, November 10th. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a report on Wednesday, September 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Wednesday, November 4th. HC Wainwright reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Finally, Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, November 10th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, TriSalus Life Sciences has an average rating of “Moderate Buy” and an average target price of $9.20.
View Our Latest Report on TLSI
Institutional Investors Weigh In On TriSalus Life Sciences
A number of large investors have recently added to or reduced their stakes in TLSI. Cura Wealth Advisors LLC purchased a new stake in shares of TriSalus Life Sciences in the second quarter valued at about $36,000. New York State Common Retirement Fund acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $48,000. Russell Investments Group Ltd. acquired a new position in shares of TriSalus Life Sciences in the third quarter worth $68,000. Virtu Financial LLC purchased a new stake in TriSalus Life Sciences during the 3rd quarter worth about $79,000. Finally, Provenance Wealth Advisors LLC acquired a new position in TriSalus Life Sciences in the 3rd quarter valued at about $94,000. 2.58% of the stock is owned by institutional investors and hedge funds.
About TriSalus Life Sciences
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Recommended Stories
- Five stocks we like better than TriSalus Life Sciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
